Page last updated: 2024-08-22

trimetazidine and Diabetic Cardiomyopathies

trimetazidine has been researched along with Diabetic Cardiomyopathies in 6 studies

Research

Authors	Studies
Jovanović, A; Liu, XY; Tan, W; Tang, SG; Wang, HH; Wang, SP	1
Amaral, N; Okonko, DO	1
Ding, WY; Li, Y; Tang, MX; Wang, F; Wang, ZH; Zhang, L; Zhang, W; Zhang, Y; Zhong, M	1
Cen, XJ; Ding, YH; Huang, DS; Jin, QY; Qian, LY; Zhu, XX; Zou, H	1
Qizhu, T; Wenmeng, W	1
Jammula, S; Kota, SK; Modi, KD; Panda, S	1

3 review(s) available for trimetazidine and Diabetic Cardiomyopathies

Article	Year
Metabolic abnormalities of the heart in type II diabetes. Diabetes & vascular disease research, 2015, Volume: 12, Issue:4 Topics: Antioxidants; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Energy Metabolism; Fatty Acids; Glucose; Humans; Mitochondria, Heart; Myocardium; Organophosphorus Compounds; Oxidative Phosphorylation; Oxidative Stress; Perhexiline; Ranolazine; Trimetazidine; Ubiquinone	2015
Trimetazidine in conditions other than coronary disease, old drug, new tricks? International journal of cardiology, 2017, May-01, Volume: 234 Topics: Acetyl-CoA C-Acyltransferase; Antineoplastic Agents; Chemically-Induced Disorders; Coronary Artery Disease; Diabetic Cardiomyopathies; Drug Repositioning; Humans; Kidney Diseases; Mitochondria, Heart; Trimetazidine; Vasodilator Agents	2017
Effect of diabetes on alteration of metabolism in cardiac myocytes: therapeutic implications. Diabetes technology & therapeutics, 2011, Volume: 13, Issue:11 Topics: Adenosine Triphosphate; Collagen; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Energy Metabolism; Extracellular Matrix Proteins; Fatty Acids, Nonesterified; Female; Glycation End Products, Advanced; Humans; Insulin; Ion Channels; Male; Mitochondria, Heart; Mitochondrial Proteins; Myocytes, Cardiac; Oxygen Consumption; Trimetazidine; Uncoupling Protein 1; Vasodilator Agents; Ventricular Dysfunction	2011

3 other study(ies) available for trimetazidine and Diabetic Cardiomyopathies

Article	Year
Trimetazidine prevents diabetic cardiomyopathy by inhibiting Nox2/TRPC3-induced oxidative stress. Journal of pharmacological sciences, 2019, Volume: 139, Issue:4 Topics: Animals; Cardiotonic Agents; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; Disease Models, Animal; Male; Molecular Targeted Therapy; NADPH Oxidase 2; Oxidative Stress; Rats, Wistar; Trimetazidine; TRPC Cation Channels	2019
Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy. Journal of translational medicine, 2016, 04-27, Volume: 14, Issue:1 Topics: Adenylate Kinase; Animals; Apoptosis; Autophagy; Blood Glucose; Catheterization; Collagen; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Diastole; Disease Models, Animal; Fibrosis; Glucose Intolerance; Insulin; Male; Phosphorylation; Rats, Sprague-Dawley; Signal Transduction; Trimetazidine; Ventricular Dysfunction, Left	2016
Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy. Medical hypotheses, 2011, Volume: 76, Issue:2 Topics: Animals; Diabetes Mellitus; Diabetic Cardiomyopathies; Heart Failure; Humans; Male; Mice; Mice, Inbred C57BL; Models, Theoretical; Myocardial Ischemia; Myocardium; Research Design; Risk Factors; Treatment Outcome; Trimetazidine; Vasodilator Agents	2011